The Effect of Xanthine Oxidase Inhibition Upon Ejection Fraction in Heart Failure Patients: La Plata Study

Horacio E. Cingolani, Juan A. Plastino, Eduardo M. Escudero, Brian Mangal, Joanne Brown, Néstor G. Pérez

Research output: Contribution to journalArticle

Abstract

Background: Reactive oxygen species (ROS) have been linked to hypertrophy, remodeling and abnormal excitation-contraction coupling. Previous data demonstrated that an increase in oxidative stress is associated to the pathogenesis of congestive heart failure (CHF). We examined whether inhibition of the superoxide anion (·O 2 -)-generating enzyme xanthine oxidase (XO) with oxypurinol may improve cardiac function in patients with CHF. Methods and Results: A randomized, placebo-controlled, double-blind study on 60 patients (30/group) with New York Heart Association class II-III CHF, comparing 600-mg/day oxypurinol during 1 month with placebo, added to standard therapy. Effects on left ventricular ejection fraction (LVEF), serum uric acid (SUA) level, and 6-minute walking test were analyzed. SUA decreased by 16.0 ± 2.8 mg/L from baseline to Week 4 in the oxypurinol group relative to placebo (P < .01, n = 30 per group). LVEF showed an increase of 4.7 ± 2.6% from baseline to Week 4 in the oxypurinol group relative to placebo that did not reach statistical significance (P < .08). When patients with LVEF >40% at baseline were excluded, a statistically significant increase of 6.8 ± 2.8% from baseline to Week 4 was seen in the oxypurinol group relative to placebo (P < .02, n = 26 placebo, n = 21 oxypurinol). No treatment-related adverse effects or increase in walking capacity were detected. Conclusion: Inhibition of XO by oxypurinol in patients with CHF decreases SUA and improves LVEF in patients with LVEF ≤40% after 1 month of treatment.

Original languageEnglish (US)
Pages (from-to)491-498
Number of pages8
JournalJournal of cardiac failure
Volume12
Issue number7
DOIs
StatePublished - Sep 1 2006

Keywords

  • Heart failure
  • Left ventricular ejection fraction
  • Trials
  • Uric acid
  • Xanthine oxidase inhibition

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The Effect of Xanthine Oxidase Inhibition Upon Ejection Fraction in Heart Failure Patients: La Plata Study'. Together they form a unique fingerprint.

  • Cite this

    Cingolani, H. E., Plastino, J. A., Escudero, E. M., Mangal, B., Brown, J., & Pérez, N. G. (2006). The Effect of Xanthine Oxidase Inhibition Upon Ejection Fraction in Heart Failure Patients: La Plata Study. Journal of cardiac failure, 12(7), 491-498. https://doi.org/10.1016/j.cardfail.2006.05.005